GlassScriptPhysician profile
Debra Reich
NPI 1396789335
$3,129.53
in general payments reported to CMS, 2019-2025
26 companies · $487 in 2025
The $487 reported for 2025 was more than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $502 · 2020: $228 · 2021: $80.86 · 2022: $495 · 2023: $683 · 2024: $654 · 2025: $487.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,825.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,825.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $946.34 | 2019-2025 | Nucala, Trelegy Ellipta |
| Genzyme Corporation | $371.24 | 2019-2025 | |
| Optinose US, INC. | $308.34 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $246.30 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $202.76 | 2019-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $139.09 | 2022-2025 | Cuvitru |
| Inspire Medical Systems, INC. | $122.93 | 2023-2025 | Inspire |
| Pfizer INC. | $111.98 | 2019-2023 | |
| Kaleo, INC. | $93.65 | 2019-2024 | Auvi-Q |
| Stryker Corporation | $82.32 | 2019 | |
| Alk-Abello, INC | $68.95 | 2023-2025 | Grastek, Ragwitek, Odactra |
| Astrazeneca Pharmaceuticals LP | $56.34 | 2024-2025 | Airsupra, Tezspire |
| Medtronic, INC. | $55.31 | 2024 | Propel |
| Vanda Pharmaceuticals INC. | $54.64 | 2022-2023 | Hetlioz |
| Arbor Pharmaceuticals, INC. | $47.74 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Blueprint Medicines Corporation | $45.53 | 2023 | Ayvakit |
| Teva Pharmaceuticals USA, INC. | $23.41 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.28 | 2022 | |
| Teleflex LLC | $21.30 | 2023 | Urolift |
| Merck Sharp & Dohme LLC | $20.82 | 2023 | |
| Biocryst US Sales Co., LLC | $19.20 | 2025 | |
| Glenmark Therapeutics INC. | $15.00 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.30 | 2019 | |
| Allergan, INC. | $13.52 | 2020 | |
| Smith+Nephew, INC. | $12.97 | 2023 | Coblation, Rapid Rhino |
| Circassia INC. | $12.27 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Debra Reich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.